The impact of the Oncotype Dx breast cancer assay in clinical practice: a systematic review and meta-analysis
JJ Carlson, JA Roth - Breast cancer research and treatment, 2013 - Springer
The impact of the Oncotype Dx (ODX) breast cancer assay on adjuvant chemotherapy (ACT)
treatment decisions has been evaluated in many previous studies. However, it can be …
treatment decisions has been evaluated in many previous studies. However, it can be …
[HTML][HTML] Clinical and molecular aspects of breast cancer: Targets and therapies
RLN Godone, GM Leitão, NB Araújo… - Biomedicine & …, 2018 - Elsevier
Breast Cancer is a complex disease characterized by the occurrence of multiple molecular
alterations. Currently, some molecular markers are in use for breast cancer diagnostic …
alterations. Currently, some molecular markers are in use for breast cancer diagnostic …
Breast-cancer-specific mortality in patients treated based on the 21-gene assay: a SEER population-based study
VI Petkov, DP Miller, N Howlader, N Gliner, W Howe… - NPJ breast …, 2016 - nature.com
Abstract The 21-gene Recurrence Score assay is validated to predict recurrence risk and
chemotherapy benefit in hormone-receptor-positive (HR+) invasive breast cancer. To …
chemotherapy benefit in hormone-receptor-positive (HR+) invasive breast cancer. To …
Impact of Oncotype DX testing on ER+ breast cancer treatment and survival in the first decade of use
Abstract Background The Oncotype DX breast recurrence score has been introduced more
than a decade ago to aid physicians in determining the need for systemic adjuvant …
than a decade ago to aid physicians in determining the need for systemic adjuvant …
[HTML][HTML] Prospective transGEICAM study of the impact of the 21-gene Recurrence Score assay and traditional clinicopathological factors on adjuvant clinical decision …
J Albanell, A Gonzalez, M Ruiz-Borrego, E Alba… - Annals of …, 2012 - Elsevier
Background This study examined the impact of the Recurrence Score (RS) in Spanish
breast cancer patients and explored the associations between clinicopathological markers …
breast cancer patients and explored the associations between clinicopathological markers …
[HTML][HTML] Systematic review of the clinical and economic value of gene expression profiles for invasive early breast cancer available in Europe
EJ Blok, E Bastiaannet, WB Van den Hout… - Cancer Treatment …, 2018 - Elsevier
Gene expression profiles with prognostic capacities have shown good performance in
multiple clinical trials. However, with multiple assays available and numerous types of …
multiple clinical trials. However, with multiple assays available and numerous types of …
Gene expression profiling and expanded immunohistochemistry tests to guide the use of adjuvant chemotherapy in breast cancer management: a systematic review …
Gene expression profiling and expanded immunohistochemistry tests to guide the use of
adjuvant chemotherapy in breast cancer man Page 1 DOI 10.3310/hta17440 HealtH tecHnology …
adjuvant chemotherapy in breast cancer man Page 1 DOI 10.3310/hta17440 HealtH tecHnology …
Adoption of gene expression profile testing and association with use of chemotherapy among women with breast cancer
MJ Hassett, SM Silver, ME Hughes… - Journal of clinical …, 2012 - ascopubs.org
Purpose Gene expression profile (GEP) testing is a relatively new technology that offers the
potential of personalized medicine to patients, yet little is known about its adoption into …
potential of personalized medicine to patients, yet little is known about its adoption into …
[HTML][HTML] Pooled analysis of prospective European studies assessing the impact of using the 21-gene Recurrence Score assay on clinical decision making in women …
J Albanell, C Svedman, J Gligorov, SDH Holt… - European Journal of …, 2016 - Elsevier
Abstract Purpose The 21-gene Recurrence Score assay (Oncotype DX) provides
prognostic/predictive information in oestrogen receptor positive (ER+) early breast cancer …
prognostic/predictive information in oestrogen receptor positive (ER+) early breast cancer …
[HTML][HTML] OPTIMA prelim: a randomised feasibility study of personalised care in the treatment of women with early breast cancer.
RC Stein, JA Dunn, JMS Bartlett… - Health Technology …, 2016 - ncbi.nlm.nih.gov
BACKGROUND There is uncertainty about the chemotherapy sensitivity of some oestrogen
receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative breast …
receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative breast …